Donanemab is a monoclonal antibody therapy being developed for patients with early Alzheimer’s disease. It works by clearing amyloid plaques from the brain and is given as a monthly intravenous infusion. Clinical trials suggest that it can slow memory loss and functional decline, with the strongest benefits seen in patients with lower to moderate levels of tau protein. The major risks include amyloid-related imaging abnormalities (ARIA) such as brain swelling or small bleeds, which require MRI monitoring. While not a cure, donanemab represents a promising disease-modifying option for early-stage Alzheimer’s.